218 related articles for article (PubMed ID: 23108144)
21. Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins.
Yang DH; Kim MH; Lee YK; Hong CY; Lee HJ; Nguyen-Pham TN; Bae SY; Ahn JS; Kim YK; Chung IJ; Kim HJ; Kalinski P; Lee JJ
Ann Hematol; 2011 Dec; 90(12):1419-26. PubMed ID: 21465188
[TBL] [Abstract][Full Text] [Related]
22. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.
Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM
Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011
[TBL] [Abstract][Full Text] [Related]
23. Identification of canine natural CD3-positive T cells expressing an invariant T-cell receptor alpha chain.
Yasuda N; Masuda K; Tsukui T; Teng A; Ishii Y
Vet Immunol Immunopathol; 2009 Dec; 132(2-4):224-31. PubMed ID: 19748683
[TBL] [Abstract][Full Text] [Related]
24. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
[TBL] [Abstract][Full Text] [Related]
25. Regulation of secondary antigen-specific CD8(+) T-cell responses by natural killer T cells.
Hong C; Lee H; Park YK; Shin J; Jung S; Kim H; Hong S; Park SH
Cancer Res; 2009 May; 69(10):4301-8. PubMed ID: 19401453
[TBL] [Abstract][Full Text] [Related]
26. [Development of a novel cancer cell therapy using enhanced cross-presentation of dendritic cells activated by innate lymphocyte].
Fujii S
Rinsho Ketsueki; 2012 May; 53(5):504-14. PubMed ID: 22728552
[No Abstract] [Full Text] [Related]
27. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
[TBL] [Abstract][Full Text] [Related]
28. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
29. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
[TBL] [Abstract][Full Text] [Related]
30. DC therapy induces long-term NK reactivity to tumors via host DC.
Shimizu K; Fujii S
Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
[TBL] [Abstract][Full Text] [Related]
31. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
[TBL] [Abstract][Full Text] [Related]
32. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.
Boczkowski D; Nair SK; Nam JH; Lyerly HK; Gilboa E
Cancer Res; 2000 Feb; 60(4):1028-34. PubMed ID: 10706120
[TBL] [Abstract][Full Text] [Related]
33. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
34. Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells.
Tripp CH; Sparber F; Hermans IF; Romani N; Stoitzner P
J Immunol; 2009 Jun; 182(12):7644-54. PubMed ID: 19494288
[TBL] [Abstract][Full Text] [Related]
35. Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand.
Petersen TR; Sika-Paotonu D; Knight DA; Dickgreber N; Farrand KJ; Ronchese F; Hermans IF
Immunol Cell Biol; 2010 Jul; 88(5):596-604. PubMed ID: 20142835
[TBL] [Abstract][Full Text] [Related]
36. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
[TBL] [Abstract][Full Text] [Related]
37. Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.
Lameris R; Schneiders FL; de Gruijl TD; van der Vliet HJ
Methods Mol Biol; 2014; 1139():155-65. PubMed ID: 24619678
[TBL] [Abstract][Full Text] [Related]
38. Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells.
Verbeke R; Lentacker I; Breckpot K; Janssens J; Van Calenbergh S; De Smedt SC; Dewitte H
ACS Nano; 2019 Feb; 13(2):1655-1669. PubMed ID: 30742405
[TBL] [Abstract][Full Text] [Related]
39. Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model.
Dong T; Yi T; Yang M; Lin S; Li W; Xu X; Hu J; Jia L; Hong X; Niu W
Biochem J; 2016 Jan; 473(1):7-19. PubMed ID: 26450924
[TBL] [Abstract][Full Text] [Related]
40. Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells.
Shimizu K; Yamasaki S; Shinga J; Sato Y; Watanabe T; Ohara O; Kuzushima K; Yagita H; Komuro Y; Asakura M; Fujii S
Cancer Res; 2016 Jul; 76(13):3756-66. PubMed ID: 27371739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]